Company News_News_Shanghai Kechow Pharma, Inc.

中文

News

Location：Home/News/Company News

Company News

Breaking News | Kechow Pharma's New Class 1 Innovative Drug Officially Included in China's New National Reimbursement Drug List, Benefiting More NRAS-mutant Advanced Melanoma Patients
2024-11-28
According to the announcement of the National Healthcare Security Administration of China on Novembe
Exciting News! The First Prescription of Kolupin® (Tunlametinib) Marks a New Era in Treating Advanced NRAS-Mutant Melanoma
2024-05-23
In March 2024, Kolupin® (Tunlametinib) was approved in China for use in patients with advanced NRAS-
Exciting News! First Domestically Developed MEK Inhibitor Kolupin (Tunlametinib) Receives NMPA Approval for Market Release
2024-03-15
The first worldwide MEK inhibitor approved for treating advanced NRAS-mutant melanoma.The first MEK
KeChow Pharma and Sinopharm Global Procurement Sign Strategic Cooperation Agreement
2024-01-24
On January 23, 2024, Shanghai Kechow Pharma Inc. (“KeChow Pharma”) and Sinopharm Global Procurement
KeChow Pharma Releases Phase I Clinical Study Data on Tunlametinib Combined with Vemurafenib for Advanced BRAF V600-Mutant Solid Tumors at ESMO 2023
2023-10-25
During the European Society for Medical Oncology (ESMO) meeting held from October 20 to 24, 2023, in
KeChow Pharma’s Animal Facility Passes Expert Inspection and Receives Experimental Animal Use License
2023-10-07
On September 27, 2023, Tianjin Municipal Bureau of Science and Technology arranged for a panel of ex

1
2
3
4
>